Navigation Links
Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
Date:3/29/2009

SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will hold a conference call and webcast on Monday, March 30, 2009 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management. Jack Lief, President and Chief Executive Officer, Dominic P. Behan, Ph.D., Senior Vice President and Chief Scientific Officer, William R. Shanahan, M.D., Vice President and Chief Medical Officer, and Christen M. Anderson, M.D., Ph.D., Vice President, Clinical Development, will host the conference call.

The conference call may be accessed by dialing 877.874.1565 for domestic callers and 719.325.4758 for international callers. Please specify to the operator that you would like to join the "Lorcaserin BLOOM Trial Results" conference call. The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-co
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
2. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
3. Critical Pharmaceuticals Enter Sustained Release hGH Arena
4. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
5. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 ... market research report is available in ... Licensing, Investments and M&A Deals and ... http://www.reportlinker.com/p0925641/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-for-May-2013-in-Pharmaceuticals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking ... Deals and Trends for May 2013 ...
(Date:6/19/2013)... 2013 A decade-long JDRF-funded study led by ... Germany , is providing a deeper ... of developing type 1 diabetes (T1D), highlighting the importance ... The study, "Seroconversion to Multiple Islet Autoantibodies and Risk ... in The Journal of the American Medical Association ...
(Date:6/19/2013)...   BioCision , a leader in advanced ... many areas of medical and scientific research, announced ... U.S. Patent Office that apply to two of ... handling to ensure the consistency of test conditions ... Patent number 8,388,912 covers CoolSink® ...
Breaking Medicine Technology:Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 2Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 3Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 4Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 5Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 6Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 7Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 8Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 9Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 10Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 11Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 12Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 13New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2
... N.J., June 15, 2011 Cordis Corporation, ... interventional vascular technology, today announced it will no longer ... in order to focus on other cardiovascular therapies where ... the manufacture of CYPHER® and CYPHER SELECT® Plus Sirolimus-Eluting ...
... American Academy of Family Physicians Foundation is excited ... Award winners. These awards recognize family medicine residency ... their communities through creative solutions. Monetary grants and ... presented to 16 residents from the following programs: ...
Cached Medicine Technology:Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent 2Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent 3Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent 4Family Medicine Residency Programs Recognized for Improving Childhood and Adult Immunizations Rates in Underserved Communities 2Family Medicine Residency Programs Recognized for Improving Childhood and Adult Immunizations Rates in Underserved Communities 3
(Date:6/19/2013)... Chicago, IL (PRWEB) June 19, 2013 Brand new ... Pakulski for the 4 day sale on the Hypertrophy Max program. ... the next 24 hours so those that are interested must act ... The all new Hypertrophy Max bonus is a free 12 month ... Del Monte. , According to Ryan Davids "Live Large TV is ...
(Date:6/19/2013)... A man returning from war is not likely to ... his debut book titled RED DANCER JOURNEY, author Rafael Fraguada pens ... home, looking for the right place and people to mend his ... from the Vietnam War, returns to New York City, he meets ... Wings, a wealthy acquaintance from a tiny Midwest college they both ...
(Date:6/19/2013)... WV (PRWEB) June 19, 2013 The ... individual used the sauna but the overall experience for ... to be positive health-wise. , Mr Mouw, whose Virgina-based ... to the Society’s statement by saying that the type ... learned of a number of counterfeit imitations which frankly, ...
(Date:6/19/2013)... New York, NY (PRWEB) June 19, 2013 ... at Mount Sinai demonstrated several new studies at ... Expo (ENDO) from June 15-18 in San Francisco.     ... self-management, as well as the role of prostastic acid ... new molecules that can stimulate the thyroid gland; revealed ...
(Date:6/19/2013)... June 19, 2013 CCA , ... Dr. John Baxter to Vice President, Health Services, effective ... Director, Mental Health Services for CCA. He will ... honor and great privilege to lead CCA's dedicated team ... opportunity to serve society and our partners as we ...
Breaking Medicine News(10 mins):Health News:New Hypertrophy Max Bonus Just Released and Only Available for 24 Hours 2Health News:Rafael Fragauda’s New Book Underlines Post Traumatic Stress Disorder 2Health News:Health Benefits of Saunas Only Viable with Properly Constructed Models, Warns Manufacturer 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 3Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 4Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 5Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 6Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 7Health News:CCA Names Dr. John Baxter Vice President, Health Services 2
... serious concern over growing problems due to use of ... Empowerment Meira Kumar today suggested effective monitoring // and ... ,There is a need to establish effective drug use ... the northeastern region,Kumar said while releasing a monograph on ...
... cholesterol-decreasing medications like millions of Americans. However she does ... she is taking part in a different clinical study ... view the benefits of Lipitor on the immune system ... sclerosis (ALS). ,Physicians at the Methodist NI's ...
... 24 years, bled to death following delivery of a stillborn baby, ... mother’s death, would now be offered a ?300,000 compensation for the ... duty in her case. ,She was admitted to the ... told that her baby had passed away in the uterus and ...
... business model for the state-of-the-art Institute of Liver and Biliary ... ,The model approved by the Cabinet at its meeting ... to be self-sufficient in nine years' time, an official spokesman ... medical equipment would be borne by Delhi Government., ,The ...
... ,The effects of zolpidem on three patients were studied for ... rehabilitation experts reveal that they are in a condition where ... interaction and responses, having signs of movement, sleep and breathing ... the patients every morning. ,An improvement was seen ...
... be a ray of hope for men, who are holed ... from available treatment measures//. An exercise by scientists involving rabbits, ... engineer an artificial penis, may be the answer for non-treatable ... adult male rabbits were introduced with a graft made from ...
Cached Medicine News:Health News:Study Aims At The Immune System In Patients With Lou Gehrig's Disease 2Health News:?300,000 Compensation For Family After Death Of Daughter Following Deliver 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: